Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1995-06-07
1997-12-02
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
A61K 9127, A61K 9133
Patent
active
056933363
ABSTRACT:
An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, cholesterol, dimyristoylphosphatidylglycerol and a cyclosporin in a mole ratio of about 28:1:3:1 to 40:1:3:1 which are stable in mammalian blood.
REFERENCES:
patent: 4608211 (1986-08-01), Handjani
patent: 4663167 (1987-05-01), Berostein
patent: 4692433 (1987-09-01), Hostetler et al.
patent: 4797285 (1989-01-01), Barenholz et al.
patent: 4812312 (1989-03-01), Lopez-Berestein et al.
patent: 4895719 (1990-01-01), Radhakrishnan et al.
patent: 4913902 (1990-04-01), Kilpatrick et al.
patent: 4952405 (1990-08-01), Young
patent: 4963362 (1990-10-01), Rahman et al.
patent: 5000887 (1991-03-01), Tenzel
patent: 5023087 (1991-06-01), Yau-Young
Hsieh et al. "Preliminary Report: The Use of Liposome-Encapsulated Cyclosporin In a Rat Model Transplanation Proceedings", vol. XVII, pp. 1397-1400. (Feb., 1985).
Stuhne-Sekalec et al. "Encapsulation of Cyclosporine by Phosphatidylinositol-Cholesterol Liposomes", Transplantation vol. 41, pp. 659-660 (1986).
Stuhne-Sekalec et al. "Co-encapsulation of Cyclosporin and Insulin by Liposomes", J. Biochem. Biophys, Methods vol. 13, pp. 23-27(1986).
Gruber et al., "liposomal Formulation Eliminates Acute Toxicity and Pump Incompatibility of Parenteral Cyclosporin", Res. vol. 5, pp. 601-607 (1989).
Stuhne-Sekalec et al. "Liposomes as Cyclosporin A Carriers: Positively Charged . . . Phosphatidylinositol", J. Microencapsulation vol. 6, pp. 177-182 (1989).
Venkataram et a. "Pharmacokinetics of Two Alternative Dosage Forms for Cyclosporine: Liposomes and Intralipid" J. Pharm. Sci. vol. 79, pp. 216-219 (1990).
Stuhne-Sekalec et al. "Liposomes as Cyclosporin A Carriers: The Influence . . . Cyclosporin A", J. Microencapsulation vol. 8, pp. 283-294 (1991).
Stuhne-Sekalec et al. "Liposomes as Carriers of Cyclosporin A, J. Microencapsulation" vol. 8, pp. 441-446 (1991).
Stuhne-Sekalec et al. "Liposomes as Cyclosporin A Carriers: ESR Study . . . Phosphatidylglycerol Liposomes", J. Microencapsulation vol. 8, pp. 455-463 (1991).
Deamer: Liposome Prep. Chap. I, p. 27 (1983).
Szoke: Ann. Rev. Biophys. Bioeng. vol. 9, p. 467 (1980).
Van de Vrie, W., "In vitro and in vivo chemosensitizing effect of cyclosprpin A on an intrinsic multidrug-resistant rat colon tumour", Cancer Research Clinical Oncology vol. 119, pp. 609-614 (1993).
Freise, Chris E., "The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome Transplantation" vol. 57, No. 6, pp. 928-932 (Mar. 1994).
Sonneveld, P, "Clinical modulation of multidrug resistance in multiple myeloma; Effect of cyclosporin on resistant tumor cells", Journal of Clinical Oncology vol. 12, No. 8, pp. 1584-1591 (Aug. 1994).
Colombo, Tina, "Cyclosporin a markedly changes the distribution of doxorubicin in mice and rats The Journal of Pharmacology and Experimental Therapeutics", vol. 269, No. 1, pp. 22-27 (1994).
Yano, Seiji, "Cyclosporin a enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotxicity of monocytes, but not of lymphocytes", J. Cancer Res. vol. 85, pp. 194-203 (Feb. 1994).
van der Graaf, Winette T.A., "Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin and vincristine in non-P-glycoprotein human small cell lung cancer cell lines", Cancer Research vol. 54, pp. 5268-5373 (Oct. 15, 1994).
Erlichman, Charles, "Phase I pharmacokinetic study of cyclosporin a combined with doxorubicin Cancer Research" vol. 53, pp.4837-4842 (Oct. 15, 1993).
Sonneveld, Pieter, "Modulation of multidrug-resistant multiple myeloma by cyclosporin", The Lancet vol. 340, No. 8814, pp. 255-259 (Aug. 1, 1992).
Samuels, Brian L., "Modulation of vinblastine resistance with cyclosporine; A phase I Study", Clinical Pharmacology & Therapeutics vol. 54, No. 4, pp. 421-429 (Oct. 1993).
Sikic, Branimir I., "Modulation of multidrug-resistance: At the Threshold", Journal of Clinical Oncology vol. 11, No 9, pp. 1629-1635 (Sep. 1993).
Thierry, Alain R., "Effect of liposomes on P-glycoprotein function in multidrug-resistant cells", Biochemical and Biophysical Research Communications vol. 187, No. 2, pp. 1098-1105 (Sep. 16, 1992).
Rahman, Aquilur, "Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells", Journal of the National Cancer Institute vol. 84, No. 24, pp. 1909-1915 (Dec. 16, 1992).
Dalton, William S., "Drug resistance modulation in the laboratory and the clinic", Seminars in Oncology vol. 20, No. 1, pp. 64-69 (Feb. 1993).
Clynes, Martin, "Cellular models for multiple drug resistance in cancer", In Vitro Cell. Dev. Biol. 29A, pp. 171-179 (Mar. 1993).
Dietel, Manfred, "Second International symposium on cytostatic drug resistance", Cancer Research vol. 53, pp. 2683-2688 (Jun. 1, 1993).
Twentyman, Peter R., "A possible role for cyclosporins in cancer chemotherapy", Anticancer Research vol. 8, pp. 985-994 (1988).
List, Alan F., "Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia", Journal of Clinical Oncology vol. 11, No. 9, pp. 1652-1660 (Sep. 1993).
Boesch, Danielle, "In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tum cells with SDZ PSC 833", Cancer Research vol. 51, pp. 4226-4233 (Aug. 15, 1991).
Yahanda, Anne M., "Phase I trial of etoposide with cyclosporine as a modular of multidrug resistance", Journal of Clinical Oncology vol. 10, No. 10, pp. 1624-1634 (Oct. 1992).
Benedicte Jachez, Rene, "Restoration of taxol sensitivity of multidrug resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-466", Journal of the National cancer Institute vol. 85, No. 6, pp. 478-483 (Mar. 17, 1993).
Slater, Lewis M., "Cyclosporin a reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro", Cyclosporin A Corrects Vincristine and Daunorubicin Resistance vol. 77, pp. 1405-1408 (Apr. 1986).
Friche, Ellen, "Comparison of cyclosporin A and SDZ PSC 833 as multidrug resistance modulators in a daunorubicin resistant Ehrlich ascites tumor", Cancer Chemotherapy and Pharmacology vol. 30,pp. 235-237 (1992).
Shoji, Y, "Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms", Cancer Letters vol. 57,p.209-218 (1991).
Hu, Xiu F., "Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines", Cancer Research vol. 50, pp. 2953-2957 (May 15, 1990).
Meador, Josephine, "Enhancement by cyclosporin A of daunorubicin efficacy in Ehrilich aacites carcinoma and murine hepatoma 129", Cancer Research vol. 47, pp. 6216-6219 (Dec. 1, 1987).
Kuhl, Jorn-Sven, "Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model", Advances in Bone Marrow Purging and Processing, pp. 25-34 (1992).
Nygren, P. "Verapamil and cyclosporin a sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca.sup.2+ concentration", Bioscience Reports vol. 10, No. 2, pp. 231-237, (1990).
Twentyman, P.R., "Chemosensitisantion by verapamil nd cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (Sorcin)", Cancer vol. 62, pp. 89-95 (1990).
Saeki, Tohru, "Human P-glycoprotein transports cyclosporin A and FK506", The Journal of Biological Chemistry vol. 268, No. 9, pp. 6077-6080 (Mar. 25, 1993).
Gilbert et al., Characterization and Administration of Cyclosporin Liposomes as a Small-Particle Aerosol, Chemical Abstrats, vol. 120, No. 14, 4 Apr. 1994, Columbus, Ohio, US, Abstract No. 173337g.
Kishore Gollamudi S.
NeXstar Pharmaceuticals, Inc.
LandOfFree
Blood stable liposomal cyclosporin formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blood stable liposomal cyclosporin formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blood stable liposomal cyclosporin formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-799144